A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma
Latest Information Update: 13 Sep 2024
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms PHILEMON
- 17 Jun 2022 Results assessing the impact of lenalidomide-based therapy on hematopoietic clones in patients with malignant lymphoproliferative disease, presented at the 27th Congress of the European Haematology Association
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 22 Apr 2020 Status changed from recruiting to completed.